Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT ID: NCT04704934
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
490 participants
INTERVENTIONAL
2021-05-21
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trastuzumab deruxtecan
Participants who will be randomized to receive a 6.4 mg/kg intravenous (IV) dose of trastuzumab deruxtecan once every 3 weeks on Day 1 of each 21-day cycle.
Trastuzumab deruxtecan
6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
Ramucirumab + paclitaxel
Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
Ramucirumab
8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Paclitaxel
80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trastuzumab deruxtecan
6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
Ramucirumab
8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Paclitaxel
80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pathologically documented gastric and GEJ adenocarcinoma that has been previously treated in the metastatic setting (unresectable, locally advanced, or metastatic disease).
* Progression on or after first-line therapy with a trastuzumab or approved trastuzumab biosimilar-containing regimen. Note: Prior neoadjuvant or adjuvant therapy with a trastuzumab-containing regimen can be counted as a line of therapy if the subject progressed on or within 6 months of completing neoadjuvant or adjuvant therapy. Prior neoadjuvant or adjuvant therapy that does not include trastuzumab will not be counted as a line of therapy regardless of the progression status of the subject.
* Locally or centrally confirmed HER2-positive (IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH) as classified by ASCO-CAP on a tumor biopsy obtained after progression on or after a first-line trastuzumab or approved trastuzumab biosimilar-containing regimen.
* Eastern Cooperative Oncology Group performance status of 0 or 1 at Screening.
* Adequate bone marrow, renal, hepatic function, and blood clotting function within 14 days of randomization.
Exclusion Criteria
* Medical history of myocardial infarction (MI) within 6 months before randomization/enrollment, symptomatic congestive heart failure (New York Heart Association Class II to IV).
* Has a QT interval corrected by Fridericia's formula (QTcF) prolongation to \>470 msec (female subjects) or \>450 msec (male subjects) based on average of the Screening triplicate12-lead ECG.
* Has a history of (non-infectious) interstitial lung disease (ILD/pneumonitis) that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
* Any autoimmune, connective tissue or inflammatory disorders (eg, rheumatoid arthritis, Sjögren syndrome, sarcoidosis, etc.) where there is documented (or a suspicion of) pulmonary involvement at the time of Screening.
* Prior complete pneumonectomy.
* Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
* Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated.
* History of severe hypersensitivity reactions to either the T-DXd or inactive ingredients in T-DXd.
* History of severe hypersensitivity reactions to other monoclonal antibodies, including ramucirumab or to any of its excipients.
* Known allergy or hypersensitivity to paclitaxel or any components used in the paclitaxel preparation or other contraindication for taxane therapy.
* Current uncontrolled infection requiring antibiotics, antivirals, or antifungals or an unexplained fever \>38.0°C during Screening visits or on the first scheduled day of dosing (at the discretion of the Investigator, participants with tumor fever may be enrolled), which in the Investigator's opinion might compromise the participant's participation in the study or affect the study outcome
* Clinically significant gastrointestinal disorder (eg, including hepatic disorders, bleeding, inflammation, occlusion, ileus, diarrhea Grade \>1, jaundice, intestinal paralysis, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, or partial bowel obstruction) in the opinion of Investigator
* Has history of receiving live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Leader
Role: STUDY_DIRECTOR
Daiichi Sankyo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Medico Especializado Alexander Fleming
Colegiales, Buenos Aires F.D., Argentina
IONC Instituto Oncologico de Cordoba - Fundacion Richardet Longo
Nueva Cordoba, Córdoba Province, Argentina
Exelsus
San Miguel de Tucumán, Tucumán Province, Argentina
Fundacion Cenit
Buenos Aires, , Argentina
UCL St. Luc
Brussels, , Belgium
Antwerp University Hospital
Edegem, , Belgium
Pôle Hospitalier Jolimont
Haine-Saint-Paul, , Belgium
UZ Leuven
Leuven, , Belgium
PERSONAL - Oncologia de Precisao e Personalizada
Belo Horizonte, , Brazil
Hospital Sirio Libanes
Brasília, , Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia LTDA
Ijuí, , Brazil
Hospital Ernesto Dornelles
Porto Alegre, , Brazil
SIM Centro de Investigacion Clinica
Temuco, Cautin, Chile
Fundacion Arturo Lopez Perez
Santiago, Santiago Metropolitan, Chile
Clinica San Carlos de Apoquindo
Santiago, Santiago Metropolitan, Chile
Anhui Provincial Hospital
Heifi, Anhui, China
Fujian Medical University - Fujian Provincial Cancer Hospital
Fuzhou, Fuijan, China
Xiamen University - The First Affiliated Hospital
Xiamen, Fujian, China
The Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
1Affiliated H of Sun Yat Sen U
Guangzhou, Guangdong, China
Hebei Medical Univ 4th Hosp
Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Zhongnan univ Xiangya hosp
Changshan, Hunan, China
Jiangsu Province Hosp
Nanjing, Jiangsu, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
1st Hosp of China Medical Univ
Shenyang, Liaoning, China
Shandong Cancer Hospital & Institute
Jinan, Shandong, China
Zhongshan Hosp Fudan Univ
Shanghai, Shanghai Municipality, China
Shanghai First People's Hosp
Shanghai, Shanghai Municipality, China
Xinjiang Medical University - Cancer Hospital
Ürümqi, Xinjiang, China
Zhejiang Medical University - Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Beijing Cancer Hospital
Beijing, , China
Peking Univ 3rd Hosp
Beijing, , China
The 1st Hospital of Jilin Univ
Changchun, , China
Sir Run Run Shaw Hospital
Hangzhou, , China
Linyi Cancer Hospital
Linyi, , China
1 Affiliated H of Nanchang U
Nanchang, , China
Fudan University - Shanghai Cancer Center
Shanghai, , China
CHU Besançon
Besançon, , France
CHRU
Brest, , France
Centre Oscar Lambret
Lille, , France
Centre Leon Berard
Lyon, , France
Hopital de la Timone
Marseille, , France
Institut de Recherche en Cancerologie de Montpellier IRCM
Montpellier, , France
Hopital Saint Antoine
Paris, , France
L Institut Mutualiste Montsouris
Paris, , France
Hopital Europeen G. Pompidou
Paris, , France
Pharmacie ICLN
Saint-Priest-en-Jarez, , France
Gustave Roussy, étage -1.
Villejuif, , France
Charité-Unimedizin Berlin
Berlin, , Germany
Uniklinikum Carl-Gustav-Carus
Dresden Sachsen, , Germany
Evang. Klin. Essen-Mitte gGmbH
Essen, , Germany
Ins. für klinische onk. Forschung
Frankfurt Am Main Hessen, , Germany
Häm-Onk. Praxis Eppendorf
Hamburg, , Germany
Asklepios Tumorzentrum Altona
Hamburg, , Germany
Uni zu Koln-Unikl. Koln
Kln Nordrhein-westfalen, , Germany
Universitares Krebszentrum
Leipzig, , Germany
Pamela Youde Nethersole Eastern Hospital
Chai Wan, , Hong Kong
Princess Margaret Hospital
Hong Kong, , Hong Kong
Queen Mary Hospital
Hong Kong, , Hong Kong
The Chinese University of Hong Kong (CUHK) - Prince of Wales Hospital (PWH) - Vascular and Interventional Radiology Foundation (VIRF) Clinical Science Centre
Hong Kong, , Hong Kong
Magyar Honvedseg Egeszs. K
Budapest, , Hungary
Debreceni Egyetem Klinikai
Debrecen, , Hungary
Tolna M. Balassa Janos Korhaz
Szekszárd, , Hungary
Cork University Hospital
Cork, , Ireland
Tallaght University Hospital
Dublin, , Ireland
Beaumont Hospital
Dublin, , Ireland
St James's Hospital
Dublin, , Ireland
Soroka Univ Medical CTR
Be'er-Sheva Southern, , Israel
Davidoff Center
Petah Tikva, , Israel
The Chaim Sheba Medical Center
Ramat Gan, , Israel
AOU Pisana
Barone, , Italy
IRCC-FPO Candiolo
Candiolo, , Italy
AOU Mater Domini
Catanzaro, , Italy
Istituto Europeo di Oncologia S.r.L Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini
Milan, , Italy
Ospedale Niguarda
Milan, , Italy
San Raffaele Hospital
Milan, , Italy
Istituto Nazionale dei Tumori
Milan, , Italy
Azienda Ospedaliero-Universitaria di Modena
Modena, , Italy
Aou Vanvitelli
Napoli, , Italy
Istituto Oncologico Veneto
Padua, , Italy
Azienda Ospedaliero-Universitaria Pisana
Pisa, , Italy
Aichi Cancer Center Hospital
Nagoya, Aichia, Japan
National Cancer Center Hospital
Chūōku, , Japan
Osaka International Cancer Institute
Chūōku, , Japan
Gifu University Hospital
Gifu, , Japan
National Cancer Center Hospital East
Kashiwa, , Japan
Kobe City Medical Center General Hospital
Kobe, , Japan
Kochi Health Sciences Center
Kochi, , Japan
The Cancer Institute Hospital of JFCR
Kōtoku, , Japan
National Hospital Organization Shikoku Cancer Center
Matsuyama, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Kindai University Hospital
Ōsaka-sayama, , Japan
Osaka University Hospital
Suita, , Japan
Sklodowska-Curie Inst Oncology
Warsaw, , Poland
Uniwersytecki Szpital Kliniczny im.Mikulicza-Radeckiego
Wroclaw, , Poland
Hospital Sra da Oliveira
Creixomil E Mariz, , Portugal
Instituto Portugues De Oncologia Do Porto Francisco Gentil, E.P.E.
Porto, , Portugal
C Hosp Tras Montes Alto Douro
Vila Real, , Portugal
S.C. Oncopremium-Team SRL
Baia Mare, , Romania
Institutul Oncologic Prof. Dr. Alexandru Trestiorean Bucuresti IOB
Bucharest, , Romania
S.C. Medisprof SRL
Cluj-Napoca, , Romania
Centrul de Oncologie Sf. Nectarie
Craiova, , Romania
SBIH Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine
Chelyabinsk, , Russia
Private Medical Institution "Euromedservice"
Saint Petersburg, , Russia
City Clinical Oncology Dispensary
Saint Petersburg, , Russia
Republican Clinical Oncology Dispensary
Ufa, , Russia
National Univ Cancer Inst SGP
Singapore, , Singapore
National Cancer Centre Singapore
Singapore, , Singapore
Kyungpook Nat Uni Chilgok Hos
Daegu, , South Korea
Chonnam National University Hwasun Hospital
Hwasun, , South Korea
Seoul Nati Univ Bundang Hosp
Seongnam, , South Korea
Korea Univ Anam Hosp
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul St. Marys Hospital
Seoul, , South Korea
Chonbuk National University Hospital - Jeonbuk Regional Cancer Center
Seoul, , South Korea
Hospital Vall d'Hebron
Barcelona, , Spain
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital Germans Trias i Pujol
Barcelona, , Spain
H. Gregorio Maranon
Madrid, , Spain
Hosp Univ Ramón y Cajal
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital de Navarra
Pamplona, , Spain
Hospital Clinico Universitario de Santiago de Compostela
Santiago de Compostela, , Spain
H. Clinico U. de Valencia
Valencia, , Spain
KMUH
Kaohsiung City, , Taiwan
CGMF-Kaohsiung Branch
Kaohsiung City, , Taiwan
China Medical Univ Hosp
Taichung, , Taiwan
National Cheng Kung Univ Hosp
Tainan, , Taiwan
National Taiwan University Hospital NTUH
Taipei, , Taiwan
MacKay Memorial Hospital
Taipei, , Taiwan
Taipei Veterans General Hosp
Taipei, , Taiwan
CGMF-Linkou Branch
Taoyuan District, , Taiwan
SBU Adana Sehir Hastanesi
Adana, , Turkey (Türkiye)
Trakya Universitesi Balkan
Edirne, , Turkey (Türkiye)
Suleyman Yalcin Seh. Hast.
Istanbul, , Turkey (Türkiye)
Inonu Uni. Turgut Ozal Tip
Malatya, , Turkey (Türkiye)
National Cancer Institute
Kyiv, , Ukraine
MedicalCenter ASKLEPION LLC
Kyiv, , Ukraine
LLC "Oncolife"
Zaporizhzhia, , Ukraine
University Hospitals Birmingham UHB NHS Foundation Trust - Queen Elizabeth Hospital Birmingham QEHB
Birmingham, , United Kingdom
Addenbrooke's Hospital
Cambridge, , United Kingdom
Velindre NHS Trust - Velindre Cancer Centre VCC
Cardiff, , United Kingdom
Ninewells Hospital
Dundee, , United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, , United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, , United Kingdom
UCLH Trust
London, , United Kingdom
Royal Marsden NHS
London, , United Kingdom
Christie Hospital
Manchester, , United Kingdom
University of Oxford, The Churchill Hospital
Oxford, , United Kingdom
Royal Marsden Sutton
Sutton, , United Kingdom
Leeds Teaching Hospitals NHS Trust
West Yorkshire, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shitara K, Van Cutsem E, Gumus M, Lonardi S, de la Fouchardiere C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025 Jul 24;393(4):336-348. doi: 10.1056/NEJMoa2503119. Epub 2025 May 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-004559-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
DS8201-A-U306
Identifier Type: -
Identifier Source: org_study_id